Pregabalin Practice Review – Accessible version of data

These tables show the data for the graphs in the Practice Review Revisiting pregabalin: Optimising safety in prescribing for neuropathic pain

How has the prescribing of pregabalin and amitriptyline nationally changed over time?

2016-17

2017-18

2018-19

2019-20

pregabalin

495754

516747

513153

502472

amitriptyline

367477

388177

423313

442671

Return to the Practice Review

 

How has the rate of prescribing of pregabalin and amitriptyline nationally changed over time?

pregabalin median

pregabalin 25th percentile

pregabalin 75th percentile

amitriptyline median

amitriptyline 25th percentile

amitriptyline 75th percentile

2016-17

10

4

19

8

3

15

2017-18

10

4

20

8

4

15

2018-19

11

5

20

9

4

17

2019-20

10

5

20

10

5

17

Return to the Practice Review

 

What percentage of patients prescribed pregabalin in 2019-20 had a total of 1-2 prescriptions or 3 or more prescriptions dispensed?

national

major city

inner regional

outer regional

remote

very remote

1-2 prescriptions

34

36

28

27

26

25

3 or more prescriptions

66

64

72

73

74

75

Return to the Practice Review

 

What percentage of patients prescribed pregabalin in 2019-20 have more than one pregabalin prescriber?

national

major city

inner regional

outer regional

remote

very remote

one prescriber

67

68

60

57

47

40

more than one prescriber

33

32

40

43

53

60

Return to the Practice Review

 

What percentage of patients prescribed pregabalin in 2019-20 (nationally) also had one or more prescriptions for opioids and/or benzodiazepines dispensed in 2019-20?

%

Neither an opioid or a benzodiazepine

35%

Either an opioid OR a benzodiazepine

47%

Both an opioid AND a benzodiazepine

19%

Return to the Practice Review